GGrantIndex
Sort

11,323 grants matching glioblastoma

T CELL FOCUSED CANCER VACCINES IN MURINE TUMOR MODELS

$102,604
Providence Portland Medical Center · R29 · FY2001 · CA

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

$102,364
Forest M White · Massachusetts Institute Of Technology · U54 · FY2019 · CA

Development of Mouse Astrocytoma Model for Preclinical Testing

$102,353
Karlyne M Reilly · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Use of CTEP portfolio compounds to counteract phenotype conversion in GBM

$102,267
Frank Pajonk · University Of California Los Angeles · R01 · FY2024 · CA

Immune Monitoring and Biospecimen Core

$102,178
Joanna Phillips · University Of California, San Francisco · U19 · FY2021 · CA

Development of Nuclear Auger Emitters for Targeted Radiotherapy

$101,904
Thomas Reiner · Sloan-Kettering Inst Can Research · R21 · FY2015 · CA

Integrative Cancer Genomics: Drivers, Pathways and Drugs

$101,640
Dana Pe'er · Columbia Univ New York Morningside · R01 · FY2014 · CA

UCLA IRB # 06-04-016 "PHASE II TRIAL OF BEVACIZUMAB IN COMBINATION WITH TEMOZ

$101,598
Timothy Cloughesy · University Of California Los Angeles · M01 · FY2008 · RR

Administrative Core

$101,519
David M. Ashley · Duke University · U19 · FY2025 · CA

MITOGENIC NEUROPEPTIDE RECEPTORS IN BRAIN TUMORS

$101,500
St. Jude Children'S Research Hospital · R29 · FY2000 · CA

Neuropathology Core

$100,928
David N Louis · Dana-Farber Cancer Inst · P01 · FY2008 · CA

Analysis of active and inactive EGFR conformations

$100,809
Kathryn M Ferguson · University Of Pennsylvania · R01 · FY2015 · CA

Steady states and cellular transitions associated with carcinogenesis and tumor progression

$100,749
James R. Heath · California Institute Of Technology · U01 · FY2017 · CA

Determination of Musashi1/CD44v6 signaling in mesenchymal glioma stem cells

$100,748
Ichiro Nakano · Ohio State University · R21 · FY2015 · CA

Evolutionary Heterogeneity of High Grade Glioma

$100,662
Erik Ladewig · Sloan-Kettering Inst Can Research · K00 · FY2021 · CA

Cell-Free DNA Methylation Patterns as a Biomarker for Tumor Biology and Clinical Outcomes for Glioblastoma Patients

$100,586
Eugene Vaios · Duke University · K38 · FY2024 · CA

Cell-Free DNA Methylation Patterns as a Biomarker for Tumor Biology and Clinical Outcomes for Glioblastoma Patients

$100,526
Eugene Vaios · Duke University · K38 · FY2025 · CA

11 Solid Tumor Therapeutics Program

$100,450
Timothy J Eberlein · Washington University · P30 · FY2022 · CA

11 Solid Tumor Therapeutics Program

$100,450
Timothy J Eberlein · Washington University · P30 · FY2024 · CA

11 Solid Tumor Therapeutics Program

$100,450
Timothy J Eberlein · Washington University · P30 · FY2023 · CA

Alternative Splicing Rewiring by Neurofibromin Isoforms Through ER-alpha and RAS Dependent Mechanisms

$100,416
Patrick Dischinger · Henry Ford Health + Michigan State University Health Sciences · K00 · FY2025 · CA

Perturbation based single cell investigation of tumor micro-environment

$100,360
Chi Zhang · Dana-Farber Cancer Inst · K00 · FY2024 · CA

Sex Differences in Blood-Brain and Blood-Tumor Barrier Dynamics in Glioblastoma

$100,270
Samuel Adam Tyler Sprowls · University Of Pittsburgh At Pittsburgh · K00 · FY2024 · CA

Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

$100,000
Christina Grek · Xequel Bio, Inc. · R44 · FY2020 · CA

METVAN: A Novel Anticancer Agent

$100,000
Paradigm Pharmaceuticals, Llc · R43 · FY2003 · CA